Pitcairn Co. Trims Holdings in Medtronic PLC $MDT

Pitcairn Co. reduced its stake in Medtronic PLC (NYSE:MDT) by 43.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 20,303 shares of the medical technology company’s stock after selling 15,648 shares during the quarter. Pitcairn Co.’s holdings in Medtronic were worth $1,934,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in MDT. Perennial Investment Advisors LLC purchased a new position in shares of Medtronic during the third quarter worth $206,000. Smith Moore & CO. raised its holdings in shares of Medtronic by 5.1% in the 3rd quarter. Smith Moore & CO. now owns 13,275 shares of the medical technology company’s stock valued at $1,264,000 after buying an additional 639 shares during the period. Orion Porfolio Solutions LLC lifted its stake in Medtronic by 28.0% during the 3rd quarter. Orion Porfolio Solutions LLC now owns 121,441 shares of the medical technology company’s stock worth $11,566,000 after acquiring an additional 26,565 shares in the last quarter. Stonebridge Capital Advisors LLC boosted its holdings in Medtronic by 0.4% during the 3rd quarter. Stonebridge Capital Advisors LLC now owns 182,724 shares of the medical technology company’s stock valued at $17,403,000 after acquiring an additional 639 shares during the period. Finally, Advisory Alpha LLC boosted its holdings in Medtronic by 19.6% during the 3rd quarter. Advisory Alpha LLC now owns 3,184 shares of the medical technology company’s stock valued at $304,000 after acquiring an additional 521 shares during the period. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Board approved a cash dividend of $0.71 for Q4 FY2026, reinforcing Medtronic’s long track record as a dividend grower and supporting income‑focused investor demand. Medtronic announces cash dividend for fourth quarter of fiscal year 2026
• Positive Sentiment: Medtronic launched the MiniMed Go Smart MDI system with the Simplera sensor in Europe, expanding its connected diabetes portfolio and addressing long‑term growth in continuous glucose monitoring and smart‑pen integration. Medtronic’s New MiniMed Go Highlights Digital Diabetes Push And Valuation Gap
• Positive Sentiment: Medtronic and GE HealthCare expanded their patient‑monitoring alliance, which could broaden distribution for products like Nellcor pulse oximetry and support recurring revenue streams. Medtronic, GE HealthCare expand patient monitoring alliance
• Positive Sentiment: Industry reports continue to rank Medtronic among leaders in biosensors and continuous glucose monitoring, supporting the company’s strategic position in a fast‑growing addressable market. Biosensors Company Evaluation Report 2025
• Neutral Sentiment: MiniMed priced its IPO at $20.00 per share for 28,000,000 shares — a procedural step that establishes a public valuation for the diabetes unit but doesn’t by itself show how Medtronic will deploy proceeds or adjust ownership. MiniMed announces pricing of initial public offering
• Negative Sentiment: MiniMed’s US IPO raised roughly $560 million — the market is interpreting the spin‑out as a catalyst for MDT selling pressure because it shifts future diabetes growth and cash flows away from the parent and may prompt portfolio rebalancing by investors. Medtronic’s diabetes unit MiniMed raises $560 million in US IPO

Insider Buying and Selling at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the sale, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.26% of the company’s stock.

Medtronic Price Performance

Shares of MDT opened at $92.96 on Friday. The firm has a market capitalization of $119.35 billion, a price-to-earnings ratio of 25.89, a PEG ratio of 2.40 and a beta of 0.71. The firm’s fifty day simple moving average is $98.80 and its 200-day simple moving average is $96.95. Medtronic PLC has a twelve month low of $79.55 and a twelve month high of $106.33. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. During the same quarter in the prior year, the company posted $1.38 earnings per share. Medtronic’s revenue for the quarter was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts forecast that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, March 27th. Medtronic’s dividend payout ratio (DPR) is 79.11%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on MDT. Robert W. Baird reduced their price target on shares of Medtronic from $103.00 to $100.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 18th. Jefferies Financial Group reaffirmed a “hold” rating and set a $110.00 target price on shares of Medtronic in a research note on Wednesday, November 19th. Wells Fargo & Company started coverage on shares of Medtronic in a research report on Friday, January 30th. They issued an “overweight” rating and a $114.00 price target for the company. Royal Bank Of Canada boosted their price target on shares of Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 19th. Finally, The Goldman Sachs Group set a $111.00 price objective on Medtronic and gave the company a “neutral” rating in a research note on Wednesday, November 19th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $110.74.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).